Stryker Corporation (SYK) Q2 2025 Earnings Call Transcript

Stryker Corporation (SYK) reported strong Q2 2025 results, with organic sales growth of 10.2% and adjusted EPS up 11.4%, driven by robust demand across its diverse portfolio, including double-digit growth in MedSurg and Neurotechnology and high single-digit growth in Orthopedics. The company achieved a milestone of 2 million Mako robotic procedures and recorded its best-ever quarter for Mako installations, while new product launches like LIFEPAK 35 and the Pangea plating system continued to drive growth. Despite some lingering supply chain issues and integration efforts with Inari Medical, Stryker raised its full-year 2025 guidance, now expecting organic net sales growth of 9.5%-10% and adjusted EPS in the range of $13.40-$13.60, reflecting confidence in sustained procedural volumes, healthy capital demand, and continued operating margin expansion.

Analysis

Stryker Corporation reported a robust second quarter for 2025, demonstrating strong top-line momentum and operational discipline. The company delivered 10.2% organic sales growth and 11.4% adjusted EPS growth, driven by double-digit performance in its MedSurg and Neurotechnology segment (+11%) and high single-digit growth in Orthopedics (+9%). This performance was underpinned by particularly strong U.S. results, including standout organic growth in Endoscopy (+18.6%), Neurocranial (+14.8%), and Trauma and Extremities (+13.6%). A key driver remains the Mako robotic platform, which achieved a record quarter for installations and surpassed 2 million cumulative procedures, with new applications for spine and shoulder progressing as planned. Management's confidence is reflected in the raised full-year 2025 guidance, which now anticipates 9.5% to 10% organic sales growth and adjusted EPS of $13.40 to $13.60, while still targeting 100 basis points of operating margin expansion. This outlook incorporates headwinds, including a revised tariff impact of approximately $175 million and integration challenges at the recently acquired NRE (Inari) business, which is undergoing destocking and sales force restructuring. However, the company noted strong underlying procedural demand and a healthy capital order book, suggesting these issues are being actively managed.

Key Decisions for Investors

• Given the broad-based double-digit organic growth and upwardly revised full-year guidance, investors may view Stryker's current operational momentum as a strong positive signal, reinforcing its position as a core holding in the MedTech sector.
• Monitor the commercial progress of new Mako applications for spine and shoulder, as their successful full launches in 2026 are poised to be significant growth catalysts for the robotics and implant portfolio.
• Pay close attention to the performance of the NRE (Inari) acquisition in the second half of the year, as a swift recovery from the current destocking and sales force integration would validate the M&A strategy and unlock a new growth avenue in peripheral vascular.
• While U.S. growth is strong, investors should note that slower EU regulatory approvals are a constraint on international performance; approvals for key products like Pangea and Insignia could re-accelerate growth in this geography.